Jeff Evanson - Apr 17, 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Chief Commercial Officer
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Apr 17, 2023
Transactions value $
$0
Form type
4
Date filed
4/19/2023, 05:41 PM
Previous filing
Jan 24, 2023
Next filing
Mar 11, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +192K $0.00 192K Apr 17, 2023 Common Stock 192K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.